Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24916771,progression free survival,The median progression free survival was 106 days (range: 1-271).,A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916771/),d,106,8209,DB00002,Cetuximab
,16061873,maximum inhibition,"At 0.04 mg, the maximum inhibition of phospho-EGFR was 53% at 24 hours, whereas the level of inhibition decreased to 37% by 72 hours.",Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16061873/),%,53,12608,DB00002,Cetuximab
,29198065,t ½,Bioorthogonal reaction between tetrazine and trans-cyclooctene (TCO) was used for tracing cetuximab and trastuzumab in vivo with a fluorine-18 (t ½ = 109.8 min) labelled tracer.,Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),min,109.8,26440,DB00002,Cetuximab
,29198065,lag time,"With cetuximab, the highest tumour-to-blood ratios were achieved when the lag time between antibody and tracer injections was 72 h.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),h,72,26441,DB00002,Cetuximab
,29198065,tumour uptake,"For both antibodies, the tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 ± 0.1%ID/g for cetuximab and 1.5 ± 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),[%id] / [g],3.7,26442,DB00002,Cetuximab
,29198065,tumour uptake,"For both antibodies, the tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 ± 0.1%ID/g for cetuximab and 1.5 ± 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),[%id] / [g],1.5,26443,DB00002,Cetuximab
,23576486,survival times,"Median survival times were 10.1 and 7.4 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,10.1,26668,DB00002,Cetuximab
,23576486,survival times,"Median survival times were 10.1 and 7.4 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,7.4,26669,DB00002,Cetuximab
,23576486,PFS times,"Median PFS times were 5.5 and 3.3 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,5.5,26670,DB00002,Cetuximab
,23576486,PFS times,"Median PFS times were 5.5 and 3.3 months, respectively.",Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),month,3.3,26671,DB00002,Cetuximab
,23576486,Response rates,Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001).,Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),%,35.6,26672,DB00002,Cetuximab
,23576486,Response rates,Response rates were 35.6% and 19.5% (odds ratio: 2.33; 95% CI: 1.50-3.60; p = .0001).,Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23576486/),%,19.5,26673,DB00002,Cetuximab
,27631463,central volume of distribution V1,"Estimated pharmacokinetic parameters (%CV) were central volume of distribution V1 = 3.18 L (6%), peripheral volume of distribution V2 = 5.4 L (42%), elimination clearance CL = 0.57 L/d (31%), distribution clearance Q = 0.64 L/d, and zero-order elimination rate k0 = 6.72 mg/d (29%).",Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631463/),l,3.18,28790,DB00002,Cetuximab
,27631463,peripheral volume of distribution V2,"Estimated pharmacokinetic parameters (%CV) were central volume of distribution V1 = 3.18 L (6%), peripheral volume of distribution V2 = 5.4 L (42%), elimination clearance CL = 0.57 L/d (31%), distribution clearance Q = 0.64 L/d, and zero-order elimination rate k0 = 6.72 mg/d (29%).",Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631463/),l,5.4,28791,DB00002,Cetuximab
,27631463,elimination clearance CL,"Estimated pharmacokinetic parameters (%CV) were central volume of distribution V1 = 3.18 L (6%), peripheral volume of distribution V2 = 5.4 L (42%), elimination clearance CL = 0.57 L/d (31%), distribution clearance Q = 0.64 L/d, and zero-order elimination rate k0 = 6.72 mg/d (29%).",Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631463/),[l] / [d],0.57,28792,DB00002,Cetuximab
,27631463,distribution clearance Q,"Estimated pharmacokinetic parameters (%CV) were central volume of distribution V1 = 3.18 L (6%), peripheral volume of distribution V2 = 5.4 L (42%), elimination clearance CL = 0.57 L/d (31%), distribution clearance Q = 0.64 L/d, and zero-order elimination rate k0 = 6.72 mg/d (29%).",Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631463/),[l] / [d],0.64,28793,DB00002,Cetuximab
,27631463,zero-order elimination rate k0,"Estimated pharmacokinetic parameters (%CV) were central volume of distribution V1 = 3.18 L (6%), peripheral volume of distribution V2 = 5.4 L (42%), elimination clearance CL = 0.57 L/d (31%), distribution clearance Q = 0.64 L/d, and zero-order elimination rate k0 = 6.72 mg/d (29%).",Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631463/),[mg] / [d],6.72,28794,DB00002,Cetuximab
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25.8,32507,DB00002,Cetuximab
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,57.3,32508,DB00002,Cetuximab
,28395759,objective response rate,"The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),%,25,32509,DB00002,Cetuximab
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,181,32510,DB00002,Cetuximab
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,200,32511,DB00002,Cetuximab
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,132,32512,DB00002,Cetuximab
,28395759,progression-free survival (PFS),"Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different.",A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28395759/),d,121,32513,DB00002,Cetuximab
,27311401,TTP,"In cetuximab-resistant HNSCC, best tumor response was PR in 1 and DC in 5 and median TTP was 112days (range: 28-168).","Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311401/),d,112,33120,DB00002,Cetuximab
,27311401,TTP,"In platin-resistant HNSCC, best tumor response: PR in 1, DC in 3 and median TTP was 112days (range: 28-112).","Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311401/),d,112,33121,DB00002,Cetuximab
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,4.6,36048,DB00002,Cetuximab
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,5.0,36049,DB00002,Cetuximab
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,7.3,36050,DB00002,Cetuximab
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,8.3,36051,DB00002,Cetuximab
,30327312,AUC,"Patients aged ≥18 years with confirmed R/M SCCHN received intravenous patritumab (18 mg/kg loading dose; 9 mg/kg maintenance dose every 3 weeks) + cetuximab (400 mg/m2 loading dose; 250 mg/m2 maintenance dose weekly) + cisplatin (100 mg/m2 every 3 weeks) or carboplatin (AUC of 5) for six cycles or until toxicity, disease progression, or withdrawal.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),,5,38078,DB00002,Cetuximab
,30327312,AUC0-21d,"Patritumab (18 mg/kg) pharmacokinetics (N = 15) showed mean (SD) AUC0-21d of 2,619 (560) μg/day/mL and maximum concentration of 499.9 (90.4) μg/mL.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),[μg] / [d·ml],"2,619",38079,DB00002,Cetuximab
,30327312,maximum concentration,"Patritumab (18 mg/kg) pharmacokinetics (N = 15) showed mean (SD) AUC0-21d of 2,619 (560) μg/day/mL and maximum concentration of 499.9 (90.4) μg/mL.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),[μg] / [ml],499.9,38080,DB00002,Cetuximab
,30327312,Tumor response rate,Tumor response rate (complete plus partial response; N = 15) was 47%.,"Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),%,47,38081,DB00002,Cetuximab
,30327312,PFS,"Median (95% confidence interval) PFS and OS (N = 15) were 7.9 (3.7-9.7) and 13.5 (6.6-17.5) months, respectively.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),month,7.9,38082,DB00002,Cetuximab
,30327312,PFS,"Median (95% confidence interval) PFS and OS (N = 15) were 7.9 (3.7-9.7) and 13.5 (6.6-17.5) months, respectively.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),month,13.5,38083,DB00002,Cetuximab
,30327312,OS,"Median (95% confidence interval) PFS and OS (N = 15) were 7.9 (3.7-9.7) and 13.5 (6.6-17.5) months, respectively.","Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327312/),month,13.5,38084,DB00002,Cetuximab
,19730278,limit of detection,The limit of detection was 0.012 mg/L.,An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730278/),[mg] / [l],0.012,51168,DB00002,Cetuximab
,19730278,trough,"Median (range) trough and peak concentrations during the treatment were 49.6 (5.8-105.4) and 177.2 (97.5-235) mg/L, respectively.",An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730278/),[mg] / [l],49.6,51169,DB00002,Cetuximab
,19730278,peak concentrations,"Median (range) trough and peak concentrations during the treatment were 49.6 (5.8-105.4) and 177.2 (97.5-235) mg/L, respectively.",An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730278/),[mg] / [l],177.2,51170,DB00002,Cetuximab
,25080323,plasma half-life,The plasma half-life for the cetuximab-IRDye800 and cetuximab groups was equivalent (2.5 days).,IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080323/),d,2.5,52290,DB00002,Cetuximab
,25103371,area under the curve,"Patients received carboplatin (area under the curve = 2 mg/ml/min; 3 weeks on, 1 week off), cetuximab (with a loading dose of 400 mg/m(2) and then 250 mg/m(2) weekly), and dose-escalating everolimus (2.5, 5.0, 7.5, and 10 mg/day) with a 3+3 design.",Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),[mg] / [min·ml],2,56266,DB00002,Cetuximab
,25103371,objective response rate (RR),The objective response rate (RR) was 61.5% (all partial responses).,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),%,61,56267,DB00002,Cetuximab
,25103371,Progression-free survival (PFS),Progression-free survival (PFS) was 8.15 months.,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),month,8.15,56268,DB00002,Cetuximab
,31164456,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) was 4.0 mg/kg.,"A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31164456/),[mg] / [kg],4.0,70362,DB00002,Cetuximab
,28578404,residual concentrations,"When tested prospectively in a pilot study in 25 head-and-neck cancer patients, this method showed that patients with clinical benefit had cetixumab residual concentrations higher than non-responding patients (i.e., 49 ± 16.3 µg/ml VS. 25.8 ± 17 µg/ml, p < 0.01 t test).",A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578404/),[μg] / [ml],49,76636,DB00002,Cetuximab
,28578404,residual concentrations,"When tested prospectively in a pilot study in 25 head-and-neck cancer patients, this method showed that patients with clinical benefit had cetixumab residual concentrations higher than non-responding patients (i.e., 49 ± 16.3 µg/ml VS. 25.8 ± 17 µg/ml, p < 0.01 t test).",A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578404/),[μg] / [ml],25.8,76637,DB00002,Cetuximab
,23153506,maximum tolerated dose,"Of the 26 patients assessed for the primary endpoint, two who received a dose of 60 mg/m(2) had dose-limiting toxicities (one had neutropenia and the other had anaemia); therefore, the maximum tolerated dose was defined as 50 mg/m(2).","Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153506/),[mg] / [m],50,85121,DB00002,Cetuximab
,21953502,central volume of distribution V(1),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,2.96,86539,DB00002,Cetuximab
,21953502,peripheral volume of distribution V(2),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),l,4.65,86540,DB00002,Cetuximab
,21953502,elimination clearance CL,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.497,86541,DB00002,Cetuximab
,21953502,distribution clearance Q,"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[l] / [d],0.836,86542,DB00002,Cetuximab
,21953502,zero-order elimination rate k(0),"Estimated pharmacokinetic parameters (% standard error) were as follows: central volume of distribution V(1) = 2.96 L (4%), peripheral volume of distribution V(2) = 4.65 L (6%), elimination clearance CL = 0.497 L/d (4%), distribution clearance Q = 0.836 L/d (8%), and zero-order elimination rate k(0) = 8.71 mg/d (10%).",Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),[mg] / [d],8.71,86543,DB00002,Cetuximab
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,3,86544,DB00002,Cetuximab
,21953502,PFS,Median PFS of patients with a cetuximab residual concentration on day 14 below median value was 3.3 months as compared with 7.8 months for the other patients (P = 0.004).,Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953502/),month,7.8,86545,DB00002,Cetuximab
,18441330,confirmed response rate,"The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m(2) (N = 41) was 56%, with a median duration of 9.3 months.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),%,56,95589,DB00002,Cetuximab
,18441330,progression-free,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,8.1,95590,DB00002,Cetuximab
,18441330,overall survival times,"Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively.",Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18441330/),month,28.2,95591,DB00002,Cetuximab
,31705176,progression-free survival,"There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29).",[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31705176/),month,3.6,101018,DB00002,Cetuximab
,31705176,progression-free survival,"There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29).",[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31705176/),month,5.7,101019,DB00002,Cetuximab
,31705176,overall survival,"There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29).",[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31705176/),month,7.1,101020,DB00002,Cetuximab
,31705176,overall survival,"There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29).",[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31705176/),month,9.4,101021,DB00002,Cetuximab
,18999934,peak tumor uptakes,"Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),[dose·injected] / [gram],59.8,104903,DB00002,Cetuximab
,18999934,peak tumor uptakes,"Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),[dose·injected] / [gram],22.5,104904,DB00002,Cetuximab
,18999934,peak tumor uptakes,"Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),[dose·injected] / [gram],33.3,104905,DB00002,Cetuximab
,18999934,peak tumor uptakes,"Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),[dose·injected] / [gram],18.2,104906,DB00002,Cetuximab
,18999934,peak tumor uptakes,"Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),[dose·injected] / [gram],41.7,104907,DB00002,Cetuximab
,18999934,tumor %ID/g,"In contrast, the highest tumor %ID/g obtained in mice bearing melanoma (A375) xenografts was 6.3 +/- 1.1 at 72 hours.",Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),,6.3,104908,DB00002,Cetuximab
,18999934,%ID/g,The highest %ID/g was observed in the liver (9.3 +/- 1.3 at 24 hours) and the salivary glands (8.1 +/- 2.8 at 72 hours).,Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),,9.3,104909,DB00002,Cetuximab
,18999934,%ID/g,The highest %ID/g was observed in the liver (9.3 +/- 1.3 at 24 hours) and the salivary glands (8.1 +/- 2.8 at 72 hours).,Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18999934/),,8.1,104910,DB00002,Cetuximab
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,67,115438,DB00002,Cetuximab
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,80,115439,DB00002,Cetuximab
,31655131,absolute bioavailability,"In contrast, co-administration with rHuPH20 did not lead to increases in plasma exposure for trastuzumab after SC or ID administration, most likely reflecting the fact that the reported absolute bioavailability of trastuzumab (in the absence of rHuPH20) is high (∼77-99 %).",Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,∼77-99,115440,DB00002,Cetuximab
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"44,388",115941,DB00002,Cetuximab
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"39,800",115942,DB00002,Cetuximab
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"20,441",115943,DB00002,Cetuximab
,16051481,plasma AUC,"Among 14 patients, compartmental model showed no significant differences in mean plasma AUC at week 1 versus week 4 for irinotecan (44,388 versus 39,800 microg/ml/h) and cetuximab (20,441 versus 23,363 microg/ml/h), respectively.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),[μg] / [h·ml],"23,363",115944,DB00002,Cetuximab
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,16.02,115945,DB00002,Cetuximab
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,13.99,115946,DB00002,Cetuximab
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,106,115947,DB00002,Cetuximab
,16051481,Half-lifes,"Half-lifes (standard deviations) for irinotecan were 16.02 (+/-8.41) h at week 1 and 13.99 (+/-2.14) h at week 4, and for cetuximab 106 (+/-32) at week 3 and 111 (+/-30) h at week 4.",Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16051481/),h,111,115948,DB00002,Cetuximab
,33577866,Overall response rate,"Overall response rate in Parts A and B was 71.4% and 83.3%, respectively.",A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33577866/),%,71.4,119481,DB00002,Cetuximab
,33577866,Overall response rate,"Overall response rate in Parts A and B was 71.4% and 83.3%, respectively.",A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33577866/),%,83.3,119482,DB00002,Cetuximab
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,15,137032,DB00002,Cetuximab
,19940007,Response rates,"Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively.",Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940007/),%,42,137033,DB00002,Cetuximab
,27637171,clearance (CL,"The TMDD model appropriately described the monkey PK profile, which showed a decrease in clearance (CL; 1.2-0.4 ml/hr/kg) as the dose increased.","Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27637171/),[ml] / [h·kg],1.2-0.4,149822,DB00002,Cetuximab
,19446977,C(max),"After a single-dose of intravenous infusion administration of 7.5, 24 and 75 microg/kg, average C(max) ranged from 168+/-28 to 1624+/-113 microg/ml, and AUC(0-infinity) ranged from 15,739+/-1059 to 295,017+/-44,533 microg h/ml.",A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),[μg] / [ml],168,156470,DB00002,Cetuximab
,19446977,C(max),"After a single-dose of intravenous infusion administration of 7.5, 24 and 75 microg/kg, average C(max) ranged from 168+/-28 to 1624+/-113 microg/ml, and AUC(0-infinity) ranged from 15,739+/-1059 to 295,017+/-44,533 microg h/ml.",A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),[μg] / [ml],1624,156471,DB00002,Cetuximab
,19446977,AUC(0-infinity),"After a single-dose of intravenous infusion administration of 7.5, 24 and 75 microg/kg, average C(max) ranged from 168+/-28 to 1624+/-113 microg/ml, and AUC(0-infinity) ranged from 15,739+/-1059 to 295,017+/-44,533 microg h/ml.",A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),[h·μg] / [ml],"15,739",156472,DB00002,Cetuximab
,19446977,AUC(0-infinity),"After a single-dose of intravenous infusion administration of 7.5, 24 and 75 microg/kg, average C(max) ranged from 168+/-28 to 1624+/-113 microg/ml, and AUC(0-infinity) ranged from 15,739+/-1059 to 295,017+/-44,533 microg h/ml.",A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),[h·μg] / [ml],"295,017",156473,DB00002,Cetuximab
,19446977,t(1/2),C225 elimination followed a bi-exponential profile with t(1/2) ranging from 2.7+/-0.7 to 6.7+/-0.1 h.,A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),h,2.7,156474,DB00002,Cetuximab
,19446977,t(1/2),C225 elimination followed a bi-exponential profile with t(1/2) ranging from 2.7+/-0.7 to 6.7+/-0.1 h.,A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446977/),h,6.7,156475,DB00002,Cetuximab
,11459459,"terminal half-life (t(1/2,)(gamma))","The terminal half-life (t(1/2,)(gamma)) of (111)In-DTPA-PEG-C225, 21.1 h, was shorter than that of (111)In-DTPA-C225, 52.9 h.",Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459459/),h,21.1,157223,DB00002,Cetuximab
,11459459,"terminal half-life (t(1/2,)(gamma))","The terminal half-life (t(1/2,)(gamma)) of (111)In-DTPA-PEG-C225, 21.1 h, was shorter than that of (111)In-DTPA-C225, 52.9 h.",Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459459/),h,52.9,157224,DB00002,Cetuximab
,16303861,time to progression,"Median time to progression was 9.9 months [lower 95% confidence limit (CL) 7.9, upper 95% CL not reached].",Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303861/),month,9.9,157278,DB00002,Cetuximab
,19169687,overall disease control rate,The overall disease control rate (partial response + stable disease) was 58%.,A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19169687/),%,58,170410,DB00002,Cetuximab
,21051930,Tl/2,"In the single-dose phase, CMAB009 reached peak serum concentrations at the end of the infusion and then declined slowly with a Tl/2 of 77.15 ±13.96 h, 79.79 ±6.91 h, and 86.25 ±9.93 h after infusion of 100, 250, and 400 mg/m ( 2) based on a two compartmental model analysis.",Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21051930/),h,77.15,173518,DB00002,Cetuximab
,21051930,Tl/2,"In the single-dose phase, CMAB009 reached peak serum concentrations at the end of the infusion and then declined slowly with a Tl/2 of 77.15 ±13.96 h, 79.79 ±6.91 h, and 86.25 ±9.93 h after infusion of 100, 250, and 400 mg/m ( 2) based on a two compartmental model analysis.",Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21051930/),h,79.79,173519,DB00002,Cetuximab
,21051930,Tl/2,"In the single-dose phase, CMAB009 reached peak serum concentrations at the end of the infusion and then declined slowly with a Tl/2 of 77.15 ±13.96 h, 79.79 ±6.91 h, and 86.25 ±9.93 h after infusion of 100, 250, and 400 mg/m ( 2) based on a two compartmental model analysis.",Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21051930/),h,86.25,173520,DB00002,Cetuximab
,21051930,Tl/2,"After multiple infusions, serum concentrations dropped slowly and the Tl/2 was 102.25 ± 33.54 h and 118.91 ± 29.12 h based on a two compartmental model analysis.",Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21051930/),h,102.25,173521,DB00002,Cetuximab
,21051930,Tl/2,"After multiple infusions, serum concentrations dropped slowly and the Tl/2 was 102.25 ± 33.54 h and 118.91 ± 29.12 h based on a two compartmental model analysis.",Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21051930/),h,118.91,173522,DB00002,Cetuximab
,22615057,progression free survival (PFS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,2.5,175046,DB00002,Cetuximab
,22615057,overall survival (OS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,4.7,175047,DB00002,Cetuximab
,21601372,complete response (CR) rate,The complete response (CR) rate at the completion of therapy was 84%.,"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601372/),%,84,175529,DB00002,Cetuximab
,21601372,local regional control rate,The estimated 3-year local regional control rate was 72%.,"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601372/),%,72,175530,DB00002,Cetuximab
,14701780,maximum-tolerated dose,"National Cancer Institute common toxicity criteria grade 3 headache and fever occurring after the first infusion were dose limiting at 2,000 mg/wk; thus, the maximum-tolerated dose was 1,600 mg/wk.",Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14701780/),,1,178676,DB00002,Cetuximab
,18218786,V(max),"Population estimates (between-subject variability, percent coefficient of variation) of the pharmacokinetic parameters were V(max) 4.38 mg/h (15.4%), K(m) 74 mug/mL, central compartment volume V(1) 2.83 L (18.6%), peripheral compartment volume 2.43 L (56.4%), and intercompartmental clearance 0.103 L/h (97.2%).",Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218786/),[mg] / [h],4.38,181828,DB00002,Cetuximab
,18218786,K(m),"Population estimates (between-subject variability, percent coefficient of variation) of the pharmacokinetic parameters were V(max) 4.38 mg/h (15.4%), K(m) 74 mug/mL, central compartment volume V(1) 2.83 L (18.6%), peripheral compartment volume 2.43 L (56.4%), and intercompartmental clearance 0.103 L/h (97.2%).",Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218786/),[μg] / [ml],74,181829,DB00002,Cetuximab
,18218786,central compartment volume V(1),"Population estimates (between-subject variability, percent coefficient of variation) of the pharmacokinetic parameters were V(max) 4.38 mg/h (15.4%), K(m) 74 mug/mL, central compartment volume V(1) 2.83 L (18.6%), peripheral compartment volume 2.43 L (56.4%), and intercompartmental clearance 0.103 L/h (97.2%).",Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218786/),l,2.83,181830,DB00002,Cetuximab
,18218786,peripheral compartment volume,"Population estimates (between-subject variability, percent coefficient of variation) of the pharmacokinetic parameters were V(max) 4.38 mg/h (15.4%), K(m) 74 mug/mL, central compartment volume V(1) 2.83 L (18.6%), peripheral compartment volume 2.43 L (56.4%), and intercompartmental clearance 0.103 L/h (97.2%).",Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218786/),l,2.43,181831,DB00002,Cetuximab
,18218786,intercompartmental clearance,"Population estimates (between-subject variability, percent coefficient of variation) of the pharmacokinetic parameters were V(max) 4.38 mg/h (15.4%), K(m) 74 mug/mL, central compartment volume V(1) 2.83 L (18.6%), peripheral compartment volume 2.43 L (56.4%), and intercompartmental clearance 0.103 L/h (97.2%).",Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218786/),[l] / [h],0.103,181832,DB00002,Cetuximab
,24710768,overall response rate,"The overall response rate was 55.9%, including 2 complete responses (CRs).","Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),%,55.9,185047,DB00002,Cetuximab
,24710768,overall survival (OS),Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months.,"Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),month,12.6,185048,DB00002,Cetuximab
,24710768,progression-free survival (PFS),Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months.,"Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710768/),month,6.6,185049,DB00002,Cetuximab
,30348399,limits of detection,"The limits of detection were 1.28 and 52.64 ng mL-1 for BEV and CET, respectively.",Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30348399/),[ng] / [ml],1.28,190124,DB00002,Cetuximab
,30348399,limits of detection,"The limits of detection were 1.28 and 52.64 ng mL-1 for BEV and CET, respectively.",Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30348399/),[ng] / [ml],52.64,190125,DB00002,Cetuximab
,32914391,conversion yield,"SEC-HPLC revealed almost complete reaction between cetuximab-TCO and [99mTc]HYNIC-polypeptide-PEG11-Tz in vitro, with the 8:1 Tz-to-mAb reaction providing a conversion yield of 87.83 ± 3.27 %.",A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914391/),,87,193003,DB00002,Cetuximab
,32914391,tumor-to-blood ratio,"After 24, 48, and 72 h of accumulation in HCT116 tumor, the tumor-to-blood ratio of cetuximab-TCO was 0.83 ± 0.13, 1.40 ± 0.31, and 1.15 ± 0.21, respectively.",A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914391/),,0.83,193004,DB00002,Cetuximab
,32914391,tumor-to-blood ratio,"After 24, 48, and 72 h of accumulation in HCT116 tumor, the tumor-to-blood ratio of cetuximab-TCO was 0.83 ± 0.13, 1.40 ± 0.31, and 1.15 ± 0.21, respectively.",A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914391/),,1.40,193005,DB00002,Cetuximab
,32914391,tumor-to-blood ratio,"After 24, 48, and 72 h of accumulation in HCT116 tumor, the tumor-to-blood ratio of cetuximab-TCO was 0.83 ± 0.13, 1.40 ± 0.31, and 1.15 ± 0.21, respectively.",A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914391/),,1.15,193006,DB00002,Cetuximab
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00002,Cetuximab
,19208430,response rate,"The response rate was 20% (95% confidence interval [CI], 10.4% to 33.0%) and median time to disease progression was 104 days.",A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19208430/),%,20,198635,DB00002,Cetuximab
,19208430,time to disease progression,"The response rate was 20% (95% confidence interval [CI], 10.4% to 33.0%) and median time to disease progression was 104 days.",A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19208430/),d,104,198636,DB00002,Cetuximab
,19208430,overall survival (OS),The median overall survival (OS) was 7.5 months with a 1-year survival of 35%.,A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19208430/),month,7.5,198637,DB00002,Cetuximab
,21174225,objective response rate,"The objective response rate was 30.0% (95% confidence interval [CI], 14.7%-49.4%) and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95% CI, 57.7%-90.0%).","Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),%,30.,210925,DB00002,Cetuximab
,21174225,progression-free survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,5.3,210926,DB00002,Cetuximab
,21174225,overall survival,The median progression-free survival was 5.3 months and median overall survival was 10.8 months.,"Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174225/),month,10.8,210927,DB00002,Cetuximab
,16246975,area under the curve,"Patients with tumor evidence of EGFR by immunohistochemistry, performance status of 0 to 2, and measurable disease received paclitaxel 225 mg/m2 with carboplatin area under the curve = 6 on day 1 every 3 weeks.",Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16246975/),,6,218057,DB00002,Cetuximab
,16246975,time to progression,"With a median follow-up of 19 months, the median time to progression was 5 months, median survival was 11 months, and the 1- and 2-year survival rates were 40% and 16%, respectively.",Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16246975/),month,5,218058,DB00002,Cetuximab
,31788317,area under the curve [AUC],"These studies were multicenter, open-label phase II trials designed to evaluate the drug-drug interactions between cetuximab (400 mg m-2 initial dose) and cisplatin (JXBA; 100 mg m-2) or carboplatin (JXBB; area under the curve [AUC] = 5 mg × min mL-1) with or without 5-fluorouracil (5FU) in patients with advanced solid tumors.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[mg·min] / [ml],5,226887,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],194,226888,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,2.0,226889,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],192,226890,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,1.99,226891,DB00002,Cetuximab
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],14 900,226892,DB00002,Cetuximab
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (194 µg mL-1, 2.0 hour, 14 900 µg × h mL-1) and the cetuximab and cisplatin combination group (192 µg mL-1, 1.99 hour, 16 300 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],16 300,226893,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[μg] / [ml],199,226894,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,1.15,226895,DB00002,Cetuximab
,31788317,"C max, t max","The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),h,3.17,226896,DB00002,Cetuximab
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],17 200,226897,DB00002,Cetuximab
,31788317,overall AUC,"The C max, t max and overall AUC for the cetuximab group (199 µg mL-1, 1.15 hour, 17 200 µg × h mL-1) and the cetuximab and carboplatin combination group (199 µg mL-1, 3.17 h, 16 800 µg × h mL-1) were similar.",Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31788317/),[h·μg] / [ml],16 800,226898,DB00002,Cetuximab
,21629245,overall response rate,"Of 62 patients, 6 (9.7%) had objective radiographic partial responses, with an overall response rate of 10%.","Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),%,10,230734,DB00002,Cetuximab
,21629245,duration of response,Median duration of response was 9.2 months; median progression-free survival was 3.9 months.,"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),month,9.2,230735,DB00002,Cetuximab
,21629245,progression-free survival,Median duration of response was 9.2 months; median progression-free survival was 3.9 months.,"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),month,3.9,230736,DB00002,Cetuximab
,29464112,terminal half life (t½),"Similar to cetuximab, tomuzotuximab concentrations increased proportionally to dose from doses≥480 mg with a median terminal half life (t½) of 82 hours, range 55-113 hours.","Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464112/),h,82,231381,DB00002,Cetuximab
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],16.8,240172,DB00002,Cetuximab
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],13.0,240173,DB00002,Cetuximab
,15947929,elimination half life (t(1/2)),"When Cetuximab was given iv to mice, the elimination half life (t(1/2)) was 39.6, 37.8, and 42.2 h for doses of 1.0, 0.25, and 0.04 mg/inj, respectively, suggesting a similar disposition kinetics of Cetuximab within this dose range.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),h,39.6,241441,DB00002,Cetuximab
,15947929,elimination half life (t(1/2)),"When Cetuximab was given iv to mice, the elimination half life (t(1/2)) was 39.6, 37.8, and 42.2 h for doses of 1.0, 0.25, and 0.04 mg/inj, respectively, suggesting a similar disposition kinetics of Cetuximab within this dose range.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),h,37.8,241442,DB00002,Cetuximab
,15947929,elimination half life (t(1/2)),"When Cetuximab was given iv to mice, the elimination half life (t(1/2)) was 39.6, 37.8, and 42.2 h for doses of 1.0, 0.25, and 0.04 mg/inj, respectively, suggesting a similar disposition kinetics of Cetuximab within this dose range.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),h,42.2,241443,DB00002,Cetuximab
,15947929,volume of distribution (V(d)),"The volume of distribution (V(d)) ranged from 0.062 l/kg to 0.070 l/kg, suggesting that Cetuximab is primarily confined to the plasma compartment with limited peripheral tissue distribution.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[l] / [kg],0.062,241444,DB00002,Cetuximab
,15947929,volume of distribution (V(d)),"The volume of distribution (V(d)) ranged from 0.062 l/kg to 0.070 l/kg, suggesting that Cetuximab is primarily confined to the plasma compartment with limited peripheral tissue distribution.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[l] / [kg],0.070,241445,DB00002,Cetuximab
,15947929,maximum plasma concentration (C(max)),"When mice were administered with a single bolus ip administration at doses of 1, 0.25, and 0.04 mg/inj, the maximum plasma concentration (C(max)) was 407.6, 66.4, and 16.5 microg/ml.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [ml],407.6,241446,DB00002,Cetuximab
,15947929,maximum plasma concentration (C(max)),"When mice were administered with a single bolus ip administration at doses of 1, 0.25, and 0.04 mg/inj, the maximum plasma concentration (C(max)) was 407.6, 66.4, and 16.5 microg/ml.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [ml],66.4,241447,DB00002,Cetuximab
,15947929,maximum plasma concentration (C(max)),"When mice were administered with a single bolus ip administration at doses of 1, 0.25, and 0.04 mg/inj, the maximum plasma concentration (C(max)) was 407.6, 66.4, and 16.5 microg/ml.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [ml],16.5,241448,DB00002,Cetuximab
,15947929,area under the curve of plasma drug concentration (AUC),"The area under the curve of plasma drug concentration (AUC) was 19212.4, 3182.4, and 534.5 microg/ml h, for 1.0, 0.25, and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [h·ml],19212.4,241449,DB00002,Cetuximab
,15947929,area under the curve of plasma drug concentration (AUC),"The area under the curve of plasma drug concentration (AUC) was 19212.4, 3182.4, and 534.5 microg/ml h, for 1.0, 0.25, and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [h·ml],3182.4,241450,DB00002,Cetuximab
,15947929,area under the curve of plasma drug concentration (AUC),"The area under the curve of plasma drug concentration (AUC) was 19212.4, 3182.4, and 534.5 microg/ml h, for 1.0, 0.25, and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [h·ml],534.5,241451,DB00002,Cetuximab
,15947929,steady state plasma concentration (C(ss avg)),The average steady state plasma concentration (C(ss avg)) for the multiple dosing schedule was estimated to be 73.1 microg/ml at 0.25 mg/inj and was considered as an active plasma drug concentration.,Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[μg] / [ml],73.1,241452,DB00002,Cetuximab
,15947929,maximum tumoral concentration,"The maximum tumoral concentration of Cetuximab was 2.6 and 0.53 ng/mg-tumor while the tumoral drug exposure was 112.6 and 18.3 ng/mg h for 0.25 and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[ng] / [mg-tumor],2.6,241453,DB00002,Cetuximab
,15947929,maximum tumoral concentration,"The maximum tumoral concentration of Cetuximab was 2.6 and 0.53 ng/mg-tumor while the tumoral drug exposure was 112.6 and 18.3 ng/mg h for 0.25 and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[ng] / [mg-tumor],0.53,241454,DB00002,Cetuximab
,15947929,exposure,"The maximum tumoral concentration of Cetuximab was 2.6 and 0.53 ng/mg-tumor while the tumoral drug exposure was 112.6 and 18.3 ng/mg h for 0.25 and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[ng] / [h·mg],112.6,241455,DB00002,Cetuximab
,15947929,exposure,"The maximum tumoral concentration of Cetuximab was 2.6 and 0.53 ng/mg-tumor while the tumoral drug exposure was 112.6 and 18.3 ng/mg h for 0.25 and 0.04 mg/inj, respectively.",Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947929/),[ng] / [h·mg],18.3,241456,DB00002,Cetuximab
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00002,Cetuximab
,16717293,area,"Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d.",Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16717293/),,5,253304,DB00002,Cetuximab
,16717293,overall response rate,"The overall response rate among patients was 36%, with no clear trend toward an increased efficacy at the highest dose of FU, and no impact of the concomitant chemotherapy regimens on cetuximab pharmacokinetics.",Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16717293/),%,36,253305,DB00002,Cetuximab
,21464917,blood clearance T(½)α,The blood clearance T(½)α of (86)Y-cetuximab (0.9-1.1 h) was faster than (86)Y-panitumumab (2.6-3.1 h).,HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464917/),h,0.9-1.1,263034,DB00002,Cetuximab
,21464917,blood clearance T(½)α,The blood clearance T(½)α of (86)Y-cetuximab (0.9-1.1 h) was faster than (86)Y-panitumumab (2.6-3.1 h).,HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21464917/),h,2.6-3.1,263035,DB00002,Cetuximab
